Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

(London – Monday, April 18th) A new industry body, the British Biosimilars Association (BBA), has been formally launched today with the sole focus of increasing the understanding and use of biosimilar medicines in the UK.

The BBA is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilar medicines. BBA members’ core focus will be ensuring patients can benefit from these lifesaving and life changing medicines to the same extent as those elsewhere in Europe. Currently, the UK lags behind some European countries in the take-up of biosimilar medicines. Restricting patient access to these medicines costs the NHS money that could be used for other treatments.

Download 336.8 KB